Aura Biosciences reported a net loss of $45.6 million for Q2 2026 and announced an organizational realignment to focus on ocular oncology, reducing its workforce by approximately 20% with estimated restructuring costs of $2.9–$3.2 million. The company appointed Susan Abu-Absi as Chief Operating Officer and Amy Elazzouzi as interim principal financial officer following the departure of CFO Anthony Gibney. Phase 3 CoMpass trial enrollment is complete, with topline data expected in H2 2027, while the NMIBC program is being deprioritized. Aura holds $323.8 million in cash and expects its runway to extend into the first half of 2029. The company operates as a clinical-stage biotechnology firm developing bel-sar for ocular cancers.

Aura Biosciences, Inc. expanded its Board of Directors from six to seven members following the unanimous appointment of Jeremy Bender, Ph.D., M.B.A., as a Class II director. Effective July 7, 2026, Dr. Bender will also serve on the Compensation and Nominating and Corporate Governance Committees. His term expires at the 2029 annual meeting of stockholders. As part of his appointment, Dr. Bender received an initial one-time stock option award for 60,000 shares and a restricted stock unit award for 30,000 shares, both vesting in equal annual installments over three years. The company also detailed its amended and restated Non-Employee Director Compensation Policy, which includes updated annual retainers and equity award structures. Aura Biosciences, Inc. is a biotechnology company focused on developing therapies for ocular diseases.